R&D JP Morgan 2023 - Astrocyte Pharmaceuticals pharmaphorum spoke with Astrocyte's Kevin Sheth, William Korinek, and James D. Lechleiter
News Avalyn seeks $300m from its IPO Pulmonary fibrosis drug developer Avalyn prices its IPO at around $300m, as Seaport and Hemab both target $180m-plus from their listings.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
